 Febuxostat is typically recommended only for people who cannot tolerate allopurinol.National Institute for Health and Clinical Excellence concluded that febuxostat is more effective than standard doses of allopurinol, but not more effective than higher doses of allopurinol.Febuxostat is in the US pregnancy category C; there are no adequate and well-controlled studies in pregnant women.